Use of effectors of glutaminyl and glutamate cyclases

Details Use of effectors of glutaminyl and glutamate cyclases Use of effectors of glutaminyl and glutamate cyclases

2004-10-15

2008-12-09

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C562S556000, C562S557000

Reexamination Certificate

active

07462599

ABSTRACT:
The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/oHeliobacter pyloriinfections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne, et al.
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5552426 (1996-09-01), Lunn et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5827898 (1998-10-01), Khandwals et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6011155 (2000-01-01), Villhauer
patent: 6107317 (2000-08-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Vollhauer
patent: 6172081 (2001-01-01), Damon
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6204248 (2001-03-01), Demopoulos et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6319893 (2001-11-01), Demuth et al.
patent: 6395780 (2002-05-01), Arlt et al.
patent: 6448282 (2002-09-01), Phillips et al.
patent: 6500804 (2002-12-01), Demuth et al.
patent: 6517824 (2003-02-01), Kohn et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 6605589 (2003-08-01), Uckun et al.
patent: 6914075 (2005-07-01), Nakano et al.
patent: 2001/0025023 (2001-09-01), Carr
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 1 130 022 (2001-09-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/01812 (1993-02-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 93/20061 (1993-10-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/22327 (1995-08-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/43278 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/20599 (1999-04-01), None
patent: WO 99/41224 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 99/64420 (1999-12-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 00/53596 (2000-09-01), None
patent: WO 00/58360 (2000-10-01), None
patent: WO 01/09169 (2001-02-01), None
patent: WO 01/32624 (2001-05-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 01/94310 (2001-12-01), None
patent: WO 01/97808 (2001-12-01), None
patent: WO 02/13821 (2002-02-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 02/20825 (2002-03-01), None
patent: WO 02/066459 (2002-08-01), None
patent: WO 02/092103 (2002-11-01), None
patent: WO 03/016335 (2003-02-01), None
patent: WO 03/070732 (2003-08-01), None
patent: WO 2004/089366 (2004-10-01), None
patent: WO 2004/098591 (2004-11-01), None
patent: WO 2004/098625 (2004-11-01), None
Panula P. (Neuroscience 82(4), 993-997, 1998).
Steinberg (The Scientist 16, 22, 2002).
Amasheh, et al.; “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed inXenopus laevisoocytes”;Journal of Physiology; (1997); 504(1): 169-174.
Ansorge, et al.; “Membrane-bound peptidases of lymphocytes; Functional implications”;Biomed. Biochim. Acta; (1991); 50(4-6); 799-807.
Arai, et al. “Synthesis of Prolyl Endopeptidase Inhibitors and Evaluation of Their Structure-Activity Relationships: In Vitro Inhibition of Prolyl Endopeptidase from Canine Brain”;Chem. Pharm. Bull.; (1993); 41(i): 1583-1588.
Ashworth, et al.; “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”;Bioorganic&Medicinol Chemistry Letters; (1996); 6(10): 1163-1166.
Augustyns, et al.; “Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV”;Eur. J. Ed. Chem.; (1997); 32: 301-309.
Bergmeier; “The Synthesis of Vicinal Amino Alcohols”;Tetrahedron; (2000); 56: 2561-2576.
Welch, et al.; “Medical Management of Non-Insulin-Dependent (Type II) Diabetes”;ADA—Third Edition; (1994); 3-4.
Campbell, et al.; “Sulphonylureas and metformin: efficacy and inadequacy”;New Antidiabetic Drugs; (1990); 33-51.
Deacon, et al.; “Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I are Rapidly Degraded from the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects”;Diabetes; (1995); 4: 1126-1131.
Deacon, et al.; “Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo”;J. of Clinical Endocrinology and Metabolism; (1996); 80: 952-957.
Dodge, et al.; “Folding and Unfolding Kinetics of the Proline-to-Alanine Mutants of Bovine Pancreatic Ribonuclease A+”;Biochemistry(1996); 35: 1548-1559.
Duncan; “Diseases of Metabolism: Detailed Methods of Diagnosis and Treatment”; (1964); 951-957.
Edwards, et al.; “Synthesis and activity of NH2- and COOH-terminal elastase recognition sequences on cotton”;J. Peptide Res.; (1999); 54: 536-543.
Endroczi, et al.; “Dipeptidyl Peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and Zn2+In Vitro”;Acta Physiologica Hungarian(1996); 75(1): 35-44.
Frohman, et al.; “Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma In Vitro and In Vivo to a biologically Inactive Product Cleaved at the NH2Terminus”;J. Clin. Invest.; (1986); 78: 906-913.
Gomez, et al.; “Relationship between endo- and expopeptidases in a processing enzyme system: Activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase”;Proc. Natl. Acad. Sci. USA; (1988); 85: 5468-5472.
Goodman & Gilman's; “Hormone and Hormone Antagonists”;The Pharmacological Basis of Therapeutics Ninth Edition; (1996); 1510.
Gutniak, et al.; “Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus”;New England J. Med.; (1992); 326: 1316-1322.
Gutniak, et al.; “Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM”;Diabetes Care; (1994); 17(9): 1039-1044.
Demuth; “Recent Developments in Inhibiting cysteine and Serine Proteases”;J. Enzyme Inhibition; (1990); 3: 249-278.
Hegen, et al.; “The T Cell Triggering Molecule Tp103 is Associated with Dipeptidyl Aminopeptidase IV Activity”;The Journal of Immunology; (1990); 144(8): 2908-2914.
Hendrick, et al.; “Glucagon-like Peptide-1-(7-37) Suppresses Hyperglycemia in Rats”;Metabolism Clinical and Experimental; (1993); 42(1): 1-6.
Krausslich & Wimmer; “Viral Proteinases”;Ann. Rev. Biochem.; (1988); 57: 701-754.
Hoffmann, et al.; “Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis”;Journal of Chromatography A; (1995); 716: 355-362.
Holst 

Affiliated with

Also associated with

Rating

Use of effectors of glutaminyl and glutamate cyclases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of effectors of glutaminyl and glutamate cyclases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of effectors of glutaminyl and glutamate cyclases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4022760